Abstract:Abstract To date, dysregulation of more than 450 RNA-binding proteins (RBPs) across a multitude of cancers has been implicated in tumorigenesis and chemoresistance. In fact, emerging evidence suggests RBPs are principal modulators of every hallmark of cancer progression. Functionally, RBPs are believed to modulate the stability, localization, and translation of transcripts encoding for virtually all known oncogenes and tumor suppressor genes. Consequently, aberrant expression of RBPs may contribute to the malignant transformation of cancer cells through enhancing the expression of oncogenes or decreasing the expression of tumors suppressor genes, such as TP53. As a potent transcription factor, TP53 is a leading regulator of numerous signaling pathways involved in tumor suppression. While mutation or deletion of TP53 contributes to tumorigenesis in more than half of all human cancers, suppression of wild-type TP53 expression also drives tumorigenesis. Thus far, multiple RBPs have been implicated in the repression of wild-type TP53, such as RNA-binding motif protein 38 (RBM38). Specifically, RBM38 interacts with eukaryotic translation initiation factor 4E (EIF4E) on the TP53 transcript, preventing EIF4E from binding to TP53 m7G cap, thus inhibiting TP53 translation. We previously demonstrated that Pep8, an 8 amino acid peptide derived from RBM38, disrupts the RBM38-EIF4E complex enhancing TP53 expression. Moreover, Pep8 alone or in combination with doxorubicin, significantly decreased tumor xenograft growth. As activation of wild-type TP53 by targeting non-genetic mechanisms that inhibit TP53 expression is a promising therapeutic tactic for malignancies that carry wild-type TP53, we are developing more efficacious Pep8 derivatives as a novel therapeutic approach for cancers that express wild-type TP53. Citation Format: Chris August Lucchesi, Jin Zhang, Xinbin Chen. Targeting the RBM38-EIF4E complex to increase wild-type p53 as a novel cancer therapeutic strategy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1037.

Mrtvp-1, a Novel P53 Target Gene with Proapoptotic Activities

RTVP-1, a Tumor Suppressor Inactivated by Methylation in Prostate Cancer.

Apoptotic Effects of the Exogenous PTEN Tumor Suppressor Gene on Human Mucoepidermoid Carcinoma Cell Line

Abstract 1037: Targeting the RBM38-EIF4E Complex to Increase Wild-Type P53 As a Novel Cancer Therapeutic Strategy

Data from Genetic Ablation of <i>rbm38</i> Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Roles of a Metastasis-Associated Molecule, RTVP-1, in Cancer Immunosurveillance

Antitumor Effected by Retroviral Expressing Wtp53 Gene Driven by Htert Promoter

Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer

PCTAIRE3: a Putative Mediator of Growth Arrest and Death Induced by CTS-1, a Dominant-Positive P53-Derived Synthetic Tumor Suppressor, in Human Malignant Glioma Cells

AMPK-beta1 subunit is a p53-independent stress responsive protein that inhibits tumor cell growth upon forced expression.

190 Novel Classes of P53 Activators for Cancer Therapy

Gene Profiling of MTA1 Identifies Novel Gene Targets and Functions.

Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site

Arginine Methyltransferase PRMT1 Regulates p53 Activity in Breast Cancer

Identification of new p53 target microRNAs by bioinformatics and functional analysis

Development of P53 Protein Transduction Therapy Using Membrane-Permeable Peptides and the Application to Oral Cancer Cells.

Secretory expression of p53(N15)-Ant following lentivirus-mediated gene transfer induces cell death in human cancer cells.

Small-Molecule Modulators Of P53 Family Signaling And Antitumor Effects In P53-Deficient Human Colon Tumor Xenografts

Inhibition Of The P53-Mdm2 Interaction By Adenovirus Delivery Of Ribosomal Protein L23 Stabilizes P53 And Induces Cell Cycle Arrest And Apoptosis In Gastric Cancer

P53-induced MRVI1 mediates carcinogenesis of colorectal cancer